IMA950, a multi-peptide vaccine containing 11 tumor-associated peptides (Rampling et al., 2016), was well-tolerated in a phase I trial of ndGBM patients (Rampling et al., 2016) and shown to induce immunogenicity in the form of CD8+ T cell responses in 63.2% of ndGBM and grade III astrocytoma patients (Migliorini et al., 2019). Here, CD8A is linked to neoplasm.